---
title: Asundexian versus Apixaban in Patients with Atrial Fibrillation
date: '2024-09-03'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39225267/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20240903182027&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: Among patients with atrial fibrillation at risk for stroke,
  treatment with asundexian at a dose of 50 mg once daily was associated with a higher
  incidence of stroke or systemic embolism than treatment with apixaban in the period
  before the trial was stopped prematurely. There were fewer major bleeding events
  with asundexian than with apixaban during this time. (Funded by Bayer; OCEANIC-AF
  ClinicalTrials.gov number, NCT05643573; EudraCT number, ...'
disable_comments: true
---
CONCLUSIONS: Among patients with atrial fibrillation at risk for stroke, treatment with asundexian at a dose of 50 mg once daily was associated with a higher incidence of stroke or systemic embolism than treatment with apixaban in the period before the trial was stopped prematurely. There were fewer major bleeding events with asundexian than with apixaban during this time. (Funded by Bayer; OCEANIC-AF ClinicalTrials.gov number, NCT05643573; EudraCT number, ...